A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price objective raised by HC Wainwright from $535.00 to $550.00 in a research note released on Friday,Benzinga reports. HC Wainwright ...

China Universal Asset Management Co. Ltd. increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 6.0% during the fourth quarter, according to its most ...

U.S. stocks fall on Friday after the White House says Canada, Mexico and China tariffs will start Saturday. Still, major indexes finish January ahead.

Vertex to see decline in earnings but double-digit revenue growth with new drug JOURNAVX and CF franchise expansion, positioning for long-term growth.

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

According to the consensus that consist of 29 analysts, the target price for Vertex is ranged from $325.00 to $591.00 with ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...